At a Glance
- Company: N/A (policy decision impacting pharma)
- Location: Washington, DC
- Headline figures: Invalidates ~$133B IEEPA tariffs; refunds pending
- Focus area: Global trade, pharma APIs from Asia
- Next steps: Lower courts on refunds; pharma eyes Section 232
What happened?
The US Supreme Court ruled 6-3 on 20 February 2026 that President Trump exceeded authority under the 1977 International Emergency Economic Powers Act (IEEPA) by imposing sweeping tariffs for trade deficits and fentanyl. Chief Justice Roberts wrote that Congress holds tariff power, rejecting vague delegation. This annuls broad “reciprocal” tariffs (10-50%) on most nations, including pharma imports.
Why does it matter?
Pharma relies on 70-80% imported APIs/active ingredients from China/India; IEEPA tariffs raised costs, disrupted chains and threatened shortages. Ruling provides relief, potentially lowering drug prices and stabilising supply, but uncertainty lingers on refunds (~$133B collected) and Trump’s pharma-specific threats (up to 250%). Section 232 probes continue.
Who’s behind it?
Plaintiffs: businesses, 12 states challenging tariffs as unconstitutional. Trump admin invoked IEEPA for “national emergency” on deficits/fentanyl. Dissent: Thomas, Kavanaugh, Alito.
How was it achieved?
Tariffs announced April 2025 (“Liberation Day”), justified via IEEPA for “unusual threat” from deficits. Lower courts struck them; SCOTUS expedited, ruling IEEPA lacks explicit tariff language vs. Constitution’s congressional power. Sector tariffs (steel) under other laws survive.
What’s next?
Lower courts handle refunds/implementation; Trump vows alternatives. Pharma monitors Section 232 national security probes on drugs. Congress may clarify delegations.
What are people saying?
Trump called ruling a “disgrace,” plans contingency. Industry: “Eases uncertainty” but “pharma threats persist.”